United Laboratories International Holdings Ltd
03933
Company Profile
Business description
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.
Contact
No. 6 Fuk Wang Street
Yuen Long Industrial Estate
New Territories
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
15,000
Stocks News & Analysis
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,498.00 | 62.10 | -0.73% |
| CAC 40 | 8,090.99 | 63.52 | -0.78% |
| DAX 40 | 22,425.93 | 138.37 | 0.62% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,658.98 | 0.39 | -0.00% |
| HKSE | 23,227.63 | 113.98 | -0.49% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,281.45 | 495.49 | -1.28% |
| NZX 50 Index | 12,307.27 | 224.45 | -1.79% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,251.90 | 56.30 | -0.68% |
| SSE Composite Index | 3,367.25 | 5.77 | -0.17% |